HIV-positive women need contraception to avoid unintended pregnancy and risk of vertical HIV transmission. We assessed acceptability of SP versus intramuscular DMPA (DMPA-IM) among HIV-positive women and their care providers in Rakai, Uganda. Women were randomized to DMPA-IM or SP at baseline, received the alternate product at 3 months, and chose their preferred method at 6 months. We determined preferences among new and experienced contraceptive injectable users who had tried both types of injection during the trial, and from providers before and after providing both types of injectables to clients.
Institutional author(s): USAID, Rakai Health Sciences Program, Makerere University
Individual author(s): Chelsea B. Polis, Gertrude F. Nakigozi, Hadijja Nakawooya, George Mondo, Frederick Makumbi, Ronald H. Gray
Publication date: November, 2013